Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2015

01-04-2015 | Research Article

Transcription factor decoy against stem cells master regulators, Nanog and Oct-4: a possible approach for differentiation therapy

Authors: Seyed Mohammad Ali Hosseini Rad, Taravat Bamdad, Majid Sadeghizadeh, Ehsan Arefian, Majid Lotfinia, Milad Ghanipour

Published in: Tumor Biology | Issue 4/2015

Login to get access

Abstract

Transcription factor decoys (TFDs) are exogenous oligonucleotides which can compete by cis-elements in promoters or enhancers for binding to TFs and downregulating gene expression in a specific manner. It is believed that tumor mass originates from cancer stem cells (CSCs) which the same with embryonic stem cells (ESCs) have the properties of both pluripotency and self-renewal (stemness). Many transcription factors such as Nanog, Oct-4, Sox2, Klf4, and Sall4 act as master regulators in the maintenance of stemness in both cell types. Differentiation therapy is based on this theory that by differentiation of CSCs, tumor mass can be eliminated with common cancer therapy methods. To our knowledge, the present study is the first report of a TFD approach against master regulator of stemness, Nanog, Oct-4, and Klf4, for downregulation purposes in P19 embryonic carcinoma stem cell. Different simple and complex decoys against Nanog, OCT-4, Sox2, and Klf4 were designed and used for this purpose. The results showed that the applied decoys especially Nanog-specific decoy decreased the expression of downstream genes.
Literature
1.
Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8:173–84.CrossRefPubMed
2.
Dass CR, Choong PF. Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy. Cancer Cell Int. 2006;6:17.CrossRefPubMedPubMedCentral
3.
Kumar R, Dammai V, Yadava PK, Kleinau S. Gene targeting by ribozyme against TNF-alpha mRNA inhibits autoimmune arthritis. Gene Ther. 2005;12:1486–93.CrossRefPubMed
4.
Wang DY, Lai BH, Sen D. A general strategy for effector-mediated control of RNA-cleaving ribozymes and DNA enzymes. J Mol Biol. 2002;318:33–43.CrossRefPubMed
5.
Bielinska A, Shivdasani RA, Zhang LQ, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science. 1990;250:997–1000.CrossRefPubMed
6.
Penolazzi L, Lambertini E, Aguiari G, del Senno L, Piva R. Modulation of estrogen receptor gene expression in human breast cancer cells: a decoy strategy with specific PCR-generated DNA fragments. Breast Cancer Res Treat. 1998;49:227–35.CrossRefPubMed
7.
Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res. 1998;82:1023–8.CrossRefPubMed
8.
Khaled AR, Butfiloski EJ, Sobel ES, Schiffenbauer J. Use of phosphorothioate-modified oligodeoxynucleotides to inhibit NF-kappaB expression and lymphocyte function. Clin Immunol Immunopathol. 1998;86:170–9.CrossRefPubMed
9.
Gao H, Xiao J, Sun Q, Lin H, Bai Y, Yang L, et al. A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anticancer effects. Mol Pharmacol. 2006;70:1621–9.CrossRefPubMed
10.
Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A. 1995;92:5855–9.CrossRefPubMedPubMedCentral
11.
Ahn JD, Kim CH, Magae J, Kim YH, Kim HJ, Park KK, et al. E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells. Biochem Biophys Res Commun. 2003;310:1048–53.CrossRefPubMed
12.
Suzuki J, Isobe M, Morishita R, Izawa A, Yamazaki S, Okubo Y, et al. E2F decoy suppresses E-selectin expression in murine cardiac allograft arteriopathy. Transplant Proc. 1999;31:2018–9.CrossRefPubMed
13.
Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A. 2003;100:4138–43.CrossRefPubMedPubMedCentral
14.
Zhang X, Liu P, Zhang B, Wang A, Yang M. Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet Cytogenet. 2010;197:46–53.CrossRefPubMed
15.
Takahashi T, Togo S, Kumamoto T, Watanabe K, Kubota T, Ichikawa Y, et al. Transfection of NF-kappaB decoy oligodeoxynucleotides into macrophages reduces murine fatal liver failure after excessive hepatectomy. J Surg Res. 2009;154:179–86.CrossRefPubMed
16.
Ohmori K, Takeda S, Miyoshi S, Minami M, Nakane S, Ohta M, et al. Attenuation of lung injury in allograft rejection using NF-kappaB decoy transfection-novel strategy for use in lung transplantation. Eur J Cardiothorac Surg. 2005;27:23–7.CrossRefPubMed
17.
Kawamura I, Morishita R, Tsujimoto S, Manda T, Tomoi M, Tomita N, et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther. 2001;8:905–12.CrossRefPubMed
18.
Chae YM, Park KK, Lee IK, Kim JK, Kim CH, Chang YC. Ring-Sp1 decoy oligonucleotide effectively suppresses extracellular matrix gene expression and fibrosis of rat kidney induced by unilateral ureteral obstruction. Gene Ther. 2006;13:430–9.CrossRefPubMed
19.
Park JH, Jo JH, Kim KH, Kim SJ, Lee WR, Park KK, et al. Antifibrotic effect through the regulation of transcription factor using ring type-Sp1 decoy oligodeoxynucleotide in carbon tetrachloride-induced liver fibrosis. J Gene Med. 2009;11:824–33.CrossRefPubMed
20.
Alper O, Bergmann-Leitner ES, Abrams S, Cho-Chung YS. Apoptosis, growth arrest and suppression of invasiveness by CRE-decoy oligonucleotide in ovarian cancer cells: protein kinase a downregulation and cytoplasmic export of CRE-binding proteins. Mol Cell Biochem. 2001;218:55–63.CrossRefPubMed
21.
Liu WM, Scott KA, Shahin S, Propper DJ. The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines. Eur J Biochem. 2004;271:2773–81.CrossRefPubMed
22.
Cho WH, Kim HT, Koo JH, Lee IK. Effect of AP-1 decoy using hemagglutinating virus of Japan-liposome on the intimal hyperplasia of the autogenous vein graft in mongrel dogs. Transplant Proc. 2006;38:2161–3.CrossRefPubMed
23.
Holschermann H, Stadlbauer TH, Wagner AH, Fingerhuth H, Muth H, Rong S, et al. STAT-1 and AP-1 decoy oligonucleotide therapy delays acute rejection and prolongs cardiac allograft survival. Cardiovasc Res. 2006;71:527–36.CrossRefPubMed
24.
Nishitsuji H, Tamura Y, Fuse T, Habu Y, Miyano-Kurosaki N, Takaku H. Inhibition of HIV-1 replication by 5'LTR decoy RNA. Nucleic Acids Res Suppl. 2001;1:141–2.CrossRef
25.
Li MJ, Kim J, Li S, Zaia J, Yee JK, Anderson J, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCr5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther. 2005;12:900–9.CrossRefPubMed
26.
Zhang J, Yamada O, Sakamoto T, Yoshida H, Araki H, Murata T, et al. Inhibition of hepatitis C virus replication by pol III-directed overexpression of RNA decoys corresponding to stem-loop structures in the NS5B coding region. Virology. 2005;342:276–85.CrossRefPubMed
27.
Ward RJ, Dirks PB. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol. 2007;2:175–89.CrossRefPubMed
28.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.CrossRefPubMed
29.
Sell S. Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev. 2005;1:197–205.CrossRefPubMed
30.
Ivanova N, Dobrin R, Lu R, Kotenko L, Levorse J, DeCoste C, et al. Dissecting self-renewal in stem cells with RNA interference. Nature. 2006;44:533–8.CrossRef
31.
Dejosez M, Krumenacker JS, Zitur LJ, Passeri M, Chu LF, Songyang Z, et al. Ronin is essential for embryogenesis and the pluripotency of mouse embryonic stem cells. Cell. 2008;133:1162–74.CrossRefPubMedPubMedCentral
32.
Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005;122:947–56.CrossRefPubMedPubMedCentral
33.
Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003;113:631–42.CrossRefPubMed
34.
Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet. 2006;38:431–40.CrossRefPubMed
35.
Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell. 2008;133:1106–17.CrossRefPubMed
36.
37.
Wu Q, Chen X, Zhang J, Loh YH, Low TY, Zhang W, et al. Sall4 interacts with Nanog and co-occupies Nanog genomic sites in embryonic stem cells. J Biol Chem. 2006;281:24090–4.CrossRefPubMed
38.
Ishiguro T, Sato A, Ohata H, Sakai H, Nakagama H, Okamoto K. Differential expression of nanog1 and nanogp8 in colon cancer cells. Biochem Biophys Res Commun. 2011;418:199–204.CrossRefPubMed
39.
Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem. 2009;284:26533–46.CrossRefPubMedPubMedCentral
40.
Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008;283:17635–51.CrossRefPubMedPubMedCentral
41.
Zhang J, Wang X, Li M, Han J, Chen B, Wang B, et al. NANOGP8 is a retrogene expressed in cancers. FEBS J. 2006;273:1723–30.CrossRefPubMed
42.
Ambady S, Malcuit C, Kashpur O, Kole D, Holmes WF, Hedblom E, et al. Expression of NANOG and NANOGP8 in a variety of undifferentiated and differentiated human cells. Int J Dev Biol. 2010;54:1743–54.CrossRefPubMedPubMedCentral
43.
Gehring WJ, Qian YQ, Billeter M, Furukubo-Tokunaga K, Schier AF, Resendez-Perez D, et al. Homeodomain-DNA recognition. Cell. 1994;78:211–23.CrossRefPubMed
44.
Jauch R, Ng CK, Saikatendu KS, Stevens RC, Kolatkar PR. Crystal structure and DNA binding of the homeodomain of the stem cell transcription factor Nanog. J Mol Biol. 2008;376:758–70.CrossRefPubMed
45.
Klemm JD, Rould MA, Aurora R, Herr W, Pabo CO. Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules. Cell. 1994;77:21–32.CrossRefPubMed
46.
Phillips K, Luisi B. The virtuoso of versatility: POU proteins that flex to fit. J Mol Biol. 2000;302:1023–39.CrossRefPubMed
47.
Yeom YI, Fuhrmann G, Ovitt CE, Brehm A, Ohbo K, Gross M, et al. Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. Development. 1996;122:881–94.PubMed
48.
Nordhoff V, Hubner K, Bauer A, Orlova I, Malapetsa A, Scholer HR. Comparative analysis of human, bovine, and murine Oct-4 upstream promoter sequences. Mamm Genome. 2001;12:309–17.CrossRefPubMed
49.
Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. 2003;17:126–40.CrossRefPubMedPubMedCentral
50.
Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol. 2000;227:239–55.CrossRefPubMed
51.
Ambrosetti DC, Basilico C, Dailey L. Synergistic activation of the fibroblast growth factor 4 enhancer by Sox2 and Oct-3 depends on protein-protein interactions facilitated by a specific spatial arrangement of factor binding sites. Mol Cell Biol. 1997;17:6321–9.CrossRefPubMedPubMedCentral
52.
Ambrosetti DC, Scholer HR, Dailey L, Basilico C. Modulation of the activity of multiple transcriptional activation domains by the DNA binding domains mediates the synergistic action of Sox2 and Oct-3 on the fibroblast growth factor-4 enhancer. J Biol Chem. 2000;275:23387–97.CrossRefPubMed
53.
Jiang J, Chan YS, Loh YH, Cai J, Tong GQ, Lim CA, et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat Cell Biol. 2008;10:353–60.CrossRefPubMed
54.
Nakatake Y, Fukui N, Iwamatsu Y, Masui S, Takahashi K, Yagi R, et al. Klf4 cooperates with Oct3/4 and Sox2 to activate the Lefty1 core promoter in embryonic stem cells. Mol Cell Biol. 2006;26:7772–82.CrossRefPubMedPubMedCentral
55.
Chew JL, Loh YH, Zhang W, Chen X, Tam WL, Yeap LS, et al. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol. 2005;25:6031–46.CrossRefPubMedPubMedCentral
56.
Odom DT, Dowell RD, Jacobsen ES, Nekludova L, Rolfe PA, Danford TW, et al. Core transcriptional regulatory circuitry in human hepatocytes. Mol Syst Biol. 2006;2:2006.0017.CrossRefPubMedPubMedCentral
57.
McBurney MW, Rogers BJ. Isolation of male embryonal carcinoma cells and their chromosome replication patterns. Dev Biol. 1982;89:503–8.CrossRefPubMed
58.
McBurney MW. P19 embryonal carcinoma cells. Int J Dev Biol. 1993;37:135–40.PubMed
59.
Choi SC, Choi JH, Shim WJ, Lim DS. P19 embryonal carcinoma cells: a new model for the study of endothelial cell differentiation. Biotechnol Lett. 2008;30:1169–75.CrossRefPubMed
60.
Liour SS, Kapitonov D, Yu RK. Expression of gangliosides in neuronal development of p19 embryonal carcinoma stem cells. J Neurosci Res. 2000;62:363–73.CrossRefPubMed
61.
Gianakopoulos PJ, Skerjanc IS. Hedgehog signaling induces cardiomyogenesis in P19 cells. J Biol Chem. 2005;280:21022–8.CrossRefPubMed
62.
Bakhshalizadeh S, Esmaeili F, Houshmand F, Shirzad H, Saedi M. Effects of selegiline, a monoamine oxidase B inhibitor, on differentiation of P19 embryonal carcinoma stem cells, into neuron-like cells. In Vitro Cell Dev Biol Anim. 2011;47:550–7.CrossRefPubMed
63.
Xu XS, Hong X, Wang G. Induction of endogenous gamma-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence. J Hematol Oncol. 2009;2:15.CrossRefPubMedPubMedCentral
64.
Niwa H, Ogawa K, Shimosato D, Adachi K. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature. 2009;460:118–22.CrossRefPubMed
65.
66.
Zhang J, Tam WL, Tong GQ, Wu Q, Chan HY, Soh BS, et al. Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. Nat Cell Biol. 2006;8:1114–23.CrossRefPubMed
67.
Omidi Y, Barar J, Heidari HR, Ahmadian S, Yazdi HA, Akhtar S. Microarray analysis of the toxicogenomics and the genotoxic potential of a cationic lipid-based gene delivery nanosystem in human alveolar epithelial a549 cells. Toxicol Mech Methods. 2008;18:369–78.CrossRefPubMed
68.
Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 2012;56:1004–14.CrossRefPubMed
69.
Chen WJ, Ho CC, Chang YL, Chen HY, Lin CA, Ling TY, et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun. 2014;5:3472.PubMed
70.
Pramfalk C, Lanner J, Andersson M, Danielsson E, Kaiser C, Renstrom IM, et al. Insulin receptor activation and down-regulation by cationic lipid transfection reagents. BMC Cell Biol. 2004;5:7.CrossRefPubMedPubMedCentral
71.
72.
Lu R, Yang A, Jin Y. Dual functions of T-box 3 (Tbx3) in the control of self-renewal and extraembryonic endoderm differentiation in mouse embryonic stem cells. J Biol chem. 2011;286:8425–36.CrossRefPubMed
73.
Hough SR, Clements I, Welch PJ, Wiederholt KA. Differentiation of mouse embryonic stem cells after RNA interference-mediated silencing of OCT4 and Nanog. Stem Cells. 2006;24:1467–75.CrossRefPubMed
74.
Hu G, Kim J, Xu Q, Leng Y, Orkin SH, Elledge SJ. A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev. 2009;23:837–48.CrossRefPubMedPubMedCentral
Metadata
Title
Transcription factor decoy against stem cells master regulators, Nanog and Oct-4: a possible approach for differentiation therapy
Authors
Seyed Mohammad Ali Hosseini Rad
Taravat Bamdad
Majid Sadeghizadeh
Ehsan Arefian
Majid Lotfinia
Milad Ghanipour
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2884-y

Other articles of this Issue 4/2015

Tumor Biology 4/2015 Go to the issue

Research Article

Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma

Research Article

LASS2/TMSG1 inhibits growth and invasion of breast cancer cell in vitro through regulation of vacuolar ATPase activity

Research Article

D-loop somatic mutations and ∼5 kb “common” deletion in mitochondrial DNA: important molecular markers to distinguish oral precancer and cancer

Research Article

Contribution of susceptibility locus at HLA class I region and environmental factors to occurrence of nasopharyngeal cancer in Northeast India

Research Article

CIZ1 promoted the growth and migration of gallbladder cancer cells

Research Article

Clinical significance of SPRR1A expression in progesterone receptor-positive breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits